Page last updated: 2024-12-08
locustakinin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
locustakinin: myotropic peptide from Locusta migratoria; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 188917 |
MeSH ID | M0201028 |
Synonyms (13)
Synonym |
---|
locustakinin |
139602-08-7 |
(2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[(2-amino-2-oxoethyl)amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]-2-[[(2s)-2-aminopropanoyl]amino]-3-phenylpropanamide |
ala-phe-ser-ser-trp-gly-nh2 |
leukokinin i, 1-de-l-aspartic acid-2-de-l-proline-5-l-serine- |
alanyl-phenylalanyl-seryl-seryl-tryptophyl-glycinamide |
lomk peptide |
locustakinin i |
(s)-n-(2-amino-2-oxoethyl)-2-((s)-2-((s)-2-((s)-2-((s)-2-aminopropanamido)-3-phenylpropanamido)-3-hydroxypropanamido)-3-hydroxypropanamido)-3-(1h-indol-3-yl)propanamide |
ala-phe-ser-ser-trp-gly-amide |
DTXSID20930517 |
17-amino-14-benzyl-4,7,10,13,16-pentahydroxy-8,11-bis(hydroxymethyl)-5-[(1h-indol-3-yl)methyl]-3,6,9,12,15-pentaazaoctadeca-3,6,9,12,15-pentaen-1-imidic acid |
AKOS040752646 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.66
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.66) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (20.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (80.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |